Abstract
Paracetamol overdose is common in developed countries but less than 10%
involve large ingestions exceeding 30g or 500mg/kg. High dose
acetylcysteine (NAC) has been proposed in patients taking large
paracetamol overdoses based on reports of hepatotoxicity despite early
initiation of NAC treatment with the commonly used 300 mg/kg intravenous
acetylcysteine regimen. The evidence from cohorts of patients treated
with the standard NAC regimen after large paracetamol overdoses shows
that it is effective in most patients. Small studies in patients whose
paracetamol concentration are above the 300mg/L nomogram line show that
modification of the standard NAC regimen to provide a total of 400-500
mg/kg NAC over 21-22h may reduce the risk of hepatotoxicity (peak
ALT>1000 IU/L) but the impact on development of hepatic
failure, liver transplantation and mortality with this approach is
presently unknown. Better risk stratification of patients taking
paracetamol overdose may allow higher dose NAC and adjunctive treatments
such as CYP2E1 inhibition and extracorporeal removal of paracetamol to
be targeted to those patients at the highest risk of hepatotoxicity
after a large paracetamol overdose.